The Mol Prospector Intelligent Preclinical Drug Discovery Platform is an AI-driven drug discovery platform specifically designed for early-stage small molecule drug R&D. Combining advanced AI algorithms with the deep expertise of the R&D team at Enlightmen Biotech Co., Ltd., the platform offers AI-driven drug discovery services, licensing of early-stage AI drug candidates, and co-development solutions. It is ideal for academic and research institutions, biotech startups, and pharmaceutical companies.

The platform can design high-potential inhibitors within 16 days, complete chemical synthesis in 2 to 3 days, and deliver in vitro-validated active lead compounds in up to 5 months. Its ADMET tool can complete toxicity predictions within minutes, effectively reducing the failure rate of animal testing.

The platform features three major competitive advantages: high predictive accuracy even with limited data, a compound synthesizability rate of up to 80% that saves up to 90% in synthesis costs, and a cell-based efficacy hit rate of 50%. These advantages make Mol Prospector a revolutionary tool for the rapid design of patentable small molecule drugs with high therapeutic potential.

ReAIX process optimization platform integrates artificial intelligence and quantum computing to deliver breakthrough manufacturing optimization solutions for pharmaceutical production. From improving efficiency to significantly reducing costs, ReAIX injects intelligent capabilities into manufacturing workflows to ensure quality and competitiveness. The platform provides manufacturing solutions across all drug modalities, ranging from biologics to small-molecule drugs, enabling scalable and high-efficiency production.

AI Drug Discovery and Development

Integrated AI Drug Discovery Platform: An AI-driven multi-model platform that accelerates drug repurposing by integrating diverse data types, multiple R&D methodologies, various analytical modalities, and a wide range of AI algorithms.